Plaque Psoriasis Clinical Trial
Official title:
In the Patient's Words: Understanding Patient Participation and Engagement in Plaque Psoriasis Clinical Trials
| NCT number | NCT06338358 |
| Other study ID # | 44519568 |
| Secondary ID | |
| Status | Not yet recruiting |
| Phase | |
| First received | |
| Last updated | |
| Start date | April 2025 |
| Est. completion date | April 2027 |
The study intends to investigate the personal experiences of plaque psoriasis patients who take part in a separate clinical study including a specific medication intervention. The major focus will be on closely following individuals' rates of trial completion and withdrawal. The data collected from this study will help improve future outcomes for all plaque psoriasis as well as those in under-represented demographic groups.
| Status | Not yet recruiting |
| Enrollment | 500 |
| Est. completion date | April 2027 |
| Est. primary completion date | April 2026 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Patients diagnosed with plaque psoriasis - Aged = 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed - Subjects willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examination. Exclusion Criteria: - Refusal of consent - Women of childbearing potential without a negative pregnancy test; or women who are lactating. - Any serious and/or unstable pre-existing medical disorders |
| Country | Name | City | State |
|---|---|---|---|
| United States | Power Life Sciences | San Francisco | California |
| Lead Sponsor | Collaborator |
|---|---|
| Power Life Sciences Inc. |
United States,
Armstrong AW, Gooderham M, Warren RB, Papp KA, Strober B, Thaci D, Morita A, Szepietowski JC, Imafuku S, Colston E, Throup J, Kundu S, Schoenfeld S, Linaberry M, Banerjee S, Blauvelt A. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023 Jan;88(1):29-39. doi: 10.1016/j.jaad.2022.07.002. Epub 2022 Jul 9. — View Citation
Armstrong AW, Puig L, Joshi A, Skup M, Williams D, Li J, Betts KA, Augustin M. Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis. JAMA Dermatol. 2020 Mar 1;156(3):258-269. doi: 10.1001/jamadermatol.2019.4029. — View Citation
Gordon KB, Langley RG, Warren RB, Okubo Y, Stein Gold L, Merola JF, Peterson L, Wixted K, Cross N, Deherder D, Thaci D. Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials. JAMA Dermatol. 2022 Jul 1;158(7):735-744. doi: 10.1001/jamadermatol.2022.1185. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Rate of patients who decide to enroll in a plaque psoriasis clinical research. | 3 months | ||
| Primary | Number of plaque psoriasis study participants who remain in clinical study until completion. | 12 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01194219 -
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
|
Phase 3 | |
| Recruiting |
NCT06030076 -
A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis
|
||
| Completed |
NCT04263610 -
Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy
|
Phase 4 | |
| Completed |
NCT02601469 -
Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis
|
Phase 2 | |
| Completed |
NCT05600036 -
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis
|
Phase 2 | |
| Completed |
NCT05375955 -
A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.
|
Phase 2 | |
| Completed |
NCT03614078 -
A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis
|
Phase 2 | |
| Not yet recruiting |
NCT05036889 -
A 16-week Randomized Evaluation of the Impact of Mind.Px Application on Response to Biologic Treatment in Patients Suffering From Plaque Psoriasis Through Clinical Utility and Health Outcomes.
|
N/A | |
| Completed |
NCT04603027 -
A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis
|
Phase 2 | |
| Completed |
NCT03638258 -
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
|
Phase 2 | |
| Completed |
NCT02881346 -
Efficacy and Tolerability of Enstilar® in Daily Practice
|
||
| Recruiting |
NCT02611349 -
Study to Evaluate the Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis
|
Phase 3 | |
| Completed |
NCT02251678 -
Evaluate the Effect of Elimune Capsules
|
Phase 1 | |
| Completed |
NCT01987843 -
Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis
|
Phase 2 | |
| Terminated |
NCT01708629 -
Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
|
Phase 3 | |
| Completed |
NCT01230138 -
Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque Psoriasis
|
Phase 2 | |
| Withdrawn |
NCT00747032 -
To Demonstrate the Superior Efficacy of NYC 0462 Ointment Over That of the Placebo in the Treatment of Plaque Psoriasis
|
Phase 3 | |
| Completed |
NCT00581100 -
Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis
|
Phase 4 | |
| Suspended |
NCT01228656 -
Effectiveness of Association Mometasone Furoate 0.1% and Salicylic Acid 5% Compared With Mometasone Furoate
|
Phase 2 | |
| Completed |
NCT00540618 -
A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis
|
Phase 2 |